Medicine Information

Limpet-M

Name: Limpet-M
Brand: Limpet-M
Rating: 4.5 (117 reviews)

Tablet2 mgOral AntidiabeticATC: A10BX

Generic Name

Metiaglinide 2 mg tablet

Manufacturer

Fictional Pharma Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
limpet m 2 mg tablet	৳ 12.00	৳ 84.00

Description

Overview of the medicine

Limpet-M 2 mg Tablet contains Metiaglinide, an oral antidiabetic medication used to manage blood sugar levels in adults with type 2 diabetes mellitus. It helps the pancreas release insulin in response to meals.

Uses & Indications

Management of type 2 diabetes mellitus in adults, as an adjunct to diet and exercise.

Used in patients who have not achieved adequate glycemic control with diet and exercise alone, or who cannot tolerate other oral antidiabetic agents.

Dosage

Adults

Initial dose is 0.5 mg to 1 mg taken 15-30 minutes before each main meal. Dose may be adjusted based on blood glucose response, up to a maximum of 4 mg per meal.

Elderly

No specific dose adjustment is generally required, but close monitoring of blood glucose is recommended due to potential for increased sensitivity to hypoglycemia.

Renal_impairment

Initial dose of 0.5 mg before each main meal. Dose adjustments should be made cautiously, monitoring blood glucose levels closely.

How to Take

Take the tablet orally 15-30 minutes before each main meal. Swallow whole with water; do not crush or chew. If a meal is skipped, the dose of Limpet-M should also be skipped.

Mechanism of Action

Metiaglinide is a meglitinide analogue that stimulates insulin secretion from pancreatic beta cells. It binds to specific receptors on beta cell membranes, leading to the closure of ATP-sensitive potassium channels. This depolarization opens calcium channels, resulting in increased intracellular calcium and subsequent insulin release.

Pharmacokinetics

Onset

Within 15-30 minutes after oral administration.

Excretion

Mainly excreted in the bile as metabolites (approximately 90%), with a small amount excreted via the kidneys.

Half life

Approximately 1 hour.

Absorption

Rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1 hour.

Metabolism

Primarily metabolized in the liver, mainly by CYP2C9 and CYP3A4.

Side Effects

Contraindications

Known hypersensitivity to Metiaglinide or any components of the tablet.
Type 1 diabetes mellitus.
Diabetic ketoacidosis (with or without coma).
Severe liver impairment.

Drug Interactions

Gemfibrozil

May significantly increase plasma concentrations of Metiaglinide, increasing the risk of hypoglycemia. Co-administration is not recommended.

Rifampicin, Phenytoin, Carbamazepine

These CYP3A4 inducers may decrease Metiaglinide levels, leading to reduced efficacy.

Clarithromycin, Itraconazole, Ketoconazole

These CYP3A4 inhibitors may increase Metiaglinide levels, requiring dose adjustment.

Corticosteroids, Thiazides, Thyroid hormones

May reduce the hypoglycemic effect of Metiaglinide, requiring dose adjustment.

Beta-blockers, ACE inhibitors, MAO inhibitors

May mask symptoms of hypoglycemia, requiring careful monitoring.

Storage

Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Overdose

Symptoms of overdose primarily include hypoglycemia (low blood sugar), which may manifest as sweating, tremor, hunger, confusion, dizziness, and weakness. Severe hypoglycemia may lead to seizures or coma. Management involves immediate administration of oral glucose (e.g., glucose tablets, sugary drinks) for conscious patients, or intravenous glucose/glucagon for unconscious patients. Close monitoring of blood glucose levels is essential.

Pregnancy & Lactation

Not recommended during pregnancy or lactation due to lack of adequate human data and potential risks to the fetus/infant. Insulin therapy is generally preferred for diabetes management during pregnancy.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per blister, 3 blisters per carton (30 tablets)10 tablets per blister, 5 blisters per carton (50 tablets)

Shelf Life

36 months from the date of manufacture

Availability

Available in pharmacies nationwide

Approval Status

Approved by national regulatory authorities

Patent Status

Under patent protection

Clinical Trials

Extensive clinical trials (Phase I, II, III) have demonstrated the efficacy and safety of Metiaglinide in improving glycemic control in adults with type 2 diabetes. Post-marketing surveillance is ongoing.

Lab Monitoring

Regular monitoring of blood glucose levels (fasting and postprandial).
HbA1c levels every 3-6 months.
Renal function tests (e.g., serum creatinine, eGFR) periodically.
Liver function tests (e.g., ALT, AST) if clinically indicated.

Doctor Notes

Emphasize patient education on hypoglycemia recognition and management.
Advise patients on consistent meal times to optimize efficacy and reduce risks.
Consider Metiaglinide for patients with irregular meal patterns or those requiring flexible dosing.
Monitor renal and hepatic function, especially in elderly patients.

Patient Guidelines

Always take this medicine 15-30 minutes before your main meals.
Do not skip meals while taking Limpet-M to avoid hypoglycemia.
Be aware of symptoms of hypoglycemia and carry a source of fast-acting sugar.
Inform your doctor about all other medications and supplements you are taking.

Missed Dose Advice

If you miss a dose, do not take a double dose. Skip the missed dose and take the next dose at the usual time before your next main meal. Do not take it if you have already started eating or finished your meal.

Driving Precautions

Limpet-M may cause hypoglycemia, which can impair your ability to concentrate and react. Patients should be advised to take precautions while driving or operating machinery, especially when starting treatment or increasing the dose.